SOLANA BEACH, Calif. - ClearPoint Neuro, Inc. (NASDAQ:CLPT), a company specializing in precision navigation for brain and spine procedures, announced today its initiation of a public offering of common stock.
The company, which provides clinical products and preclinical development services for controlled drug and device delivery to the central nervous system (CNS), will offer all the shares in this underwritten public offering.
In conjunction with the offering, ClearPoint Neuro anticipates granting the underwriters a 30-day option to purchase up to an additional 15% of the shares sold. Lake Street Capital Markets, LLC is serving as the sole book-running manager for the offering.
The offering's completion is contingent on market conditions and other factors, with no certainty regarding the finalization, size, or terms of the offering. The securities being offered are part of a shelf registration statement, which the Securities and Exchange Commission (SEC) declared effective on November 20, 2023.
Investors are encouraged to read the prospectus and related preliminary prospectus supplement filed with the SEC for more comprehensive information about ClearPoint Neuro and the offering. These documents are accessible electronically on the SEC's website.
ClearPoint Neuro's flagship product, the ClearPoint Neuro Navigation System, has received FDA clearance and is CE-marked, indicating compliance with European health, safety, and environmental protection standards.
The company has engaged with healthcare and research centers across North America, Europe, Asia, and South America, and collaborates with pharmaceutical and biotech companies, academic centers, and contract research organizations globally.
The company's public offering statements contain forward-looking information, and actual results may differ due to various risks and uncertainties, as detailed in the company's periodic filings with the SEC.
This news article is based on a press release statement and provides a factual account of ClearPoint Neuro's public stock offering without endorsement of the company's claims or potential market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.